ReviewExpert reviews in molecular medicine2011
Molecular and cellular pathobiology of Ehrlichia infection: targets for new therapeutics and immunomodulation strategies.
Review in Expert reviews in molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Prevalence of Anaplasma, Ehrlichia and Rickettsia infections in dogs in Iran: A meta-analysis study.Veterinary medicine and science · 2024Pooled it
- Molecular Characterization and Genetic Diversity of Ehrlichia canis in Naturally Infected Dogs from the Unaí Microregion, Minas Gerais, Brazil.Acta parasitologica · 2026Article
- Article
- Mitochondrial Dysfunction inTransboundary and emerging diseases · 2026Review
- Drug Design and Delivery for Intracellular Bacteria: Emerging Paradigms.Drug development research · 2025Review
- High genetic diversity of Ehrlichia canis trp36 and p28 genes in dogs from Rio de Janeiro, Brazil.Veterinary research communications · 2025Article
- Prevalence of Ehrlichia spp. in dogs and ticks in Hainan Province, China.BMC veterinary research · 2025Article
- Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells.Immunological reviews · 2025Review
- Prolonged immune response to tick-borne Ehrlichia chaffeensis infection using a genetically modified live vaccine.Vaccine · 2025Article
- Review
- Long-Term Protective Immunity againstVaccines · 2024Article
- Unraveling the Complexity: Ehrlichiosis-Induced Septic Shock and Acute Respiratory Distress Syndrome.Cureus · 2024Article
- Identification of potential nucleomodulins ofFrontiers in microbiology · 2024Article
- Molecular occurrence and genetic diversity of Ehrlichia canis in naturally infected dogs from Thailand.Scientific reports · 2023Article
- Type 1 secretion system and effectors in Rickettsiales.Frontiers in cellular and infection microbiology · 2023Review
- Antibody reactive immunomes ofFrontiers in cellular and infection microbiology · 2023Article
- Hepatocyte-specific regulation of autophagy and inflammasome activation via MyD88 during lethalFrontiers in immunology · 2023Article
- Article
- Novel Ehrlichia canis genogroup in dogs with canine ehrlichiosis in Cuba.Parasites & vectors · 2022Article
- Immunophenotypical and pathological changes in dogs experimentally infected with Ehrlichia canis.Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ehrlichia are small obligately intracellular bacteria in the order Rickettsiales that are transmitted by ticks and associated with emerging life-threatening human zoonoses. Vaccines are not available for human ehrlichiosis, and therapeutic options are limited to a single antibiotic class. New technologies for exploring host-pathogen interactions have yielded recent advances in understanding the molecular interactions between Ehrlichia and the eukaryotic host cell and identified new targets for therapeutic and vaccine development, including those that target pathogen virulence mechanisms or disrupt the processes associated with ehrlichial effector proteins. Animal models have also provided insight into immunopathological mechanisms that contribute significantly to understanding severe disease manifestations, which should lead to the development of immunomodulatory approaches for treating patients nearing or experiencing severe disease states. In this review, we discuss the recent advances in our understanding of molecular and cellular pathobiology and the immunobiology of Ehrlichia infection. We identify new molecular host-pathogen interactions that can be targets of new therapeutics, and discuss prospects for treating the immunological dysregulation during acute infection that leads to life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.